 Protalix BioTherapeutics Inc NYSE: PLX has announced an exclusive worldwide license agreement with SarcoMed USA Inc for alidornase alfa, also known as PRX110, for use in the treatment of any human respiratory disease or condition including, sarcoidosis, pulmonary fibrosis, and other related disorders via inhaled delivery. Alidornase alfa is the Companys proprietary chemically-modified plant cell-expressed recombinant form of human deoxyribonuclease I DNase I, administered through inhalation. 